Multi-omic studies promise the improved characterization of biological processes across molecular layers. However, methods for the unsupervised integration of the resulting heterogeneous datasets are lacking. We present Multi-Omics Factor Analysis (MOFA), a computational method for discovering the principal sources of variation in multi-omic datasets. MOFA infers a set of (hidden) factors that capture biological and technical sources of variability. It disentangles axes of heterogeneity that are shared across multiple modalities and those specific to individual data modalities. The learnt factors enable a variety of downstream analyses, including identification of sample subgroups, data imputation, and the detection of outlier samples. We applied MOFA to a cohort of 200 patient samples of chronic lymphocytic leukaemia, profiled for somatic mutations, RNA expression, DNA methylation and ex-vivo drug responses. MOFA identified major dimensions of disease heterogeneity, including immunoglobulin heavy chain variable region status, trisomy of chromosome 12 and previously underappreciated drivers, such as response to oxidative stress. In a second application, we used MOFA to analyse single-cell multiomics data, identifying coordinated transcriptional and epigenetic changes along cell differentiation.
Introduction
Technological advances increasingly enable multiple biological layers to be probed in parallel, ranging from genome, epigenome, transcriptome, proteome and metabolome to phenome profiling (Hasin et al, 2017) . Integrative analyses that use information across these data modalities promise to deliver more comprehensive insights into the biological systems under study. Motivated by this, multi-omic profiling is increasingly applied across biological domains, including cancer biology (Cancer Genome Atlas Research Network, 2017; Gerstung et al, 2015; Iorio et al, 2016; Mertins et al, 2016) , regulatory genomics (Chen et al, 2016) , microbiology (Kim et al, 2016) or host-pathogen biology (Soderholm et al, 2016) . Most recent technological advances have also enabled performing multi-omics analyses at the single cell level (Angermueller et al, 2016; Clark et al, 2018; Colomé-Tatché & Theis, 2018; Guo et al, 2017; Macaulay et al, 2015) . A common aim of such applications is to characterize heterogeneity between samples, as manifested in one or several of the omic data types (Ritchie et al, 2015) . Multi-omics profiling is particularly appealing if the relevant axes of variation are not known a priori, and hence may be missed by studies that consider a single data modality or targeted approaches.
A basic strategy for the integration of omics data is testing for marginal associations between different data modalities. A prominent example is molecular QTL-analysis, where large numbers of association tests are performed between individual genetic variants and gene expression levels (Consortium, 2015) or epigenetic marks (Chen et al, 2016) . While eminently useful for variant annotation, such association studies are inherently local and do not provide a coherent global map of the molecular differences between samples. A second strategy is the use kernel-or graphbased methods to combine different data types into a common similarity network between samples (Lanckriet et al, 2004; Wang et al, 2014) ; however, it is difficult to pinpoint the molecular determinants of the resulting graph structure. Related to this, there exist generalizations of other clustering methods to reconstruct discrete groups of samples based on multiple data modalities (Mo et al, 2013; Shen et al, 2009) .
A key challenge that is not sufficiently addressed by these approaches is interpretability. In particular, it would be desirable to reconstruct the underlying factors that drive the observed variation across samples, similar to the loadings in conventional principal component analysis.
These could be continuous gradients, discrete clusters, or combinations thereof. Such factors 4 al, 2013; Remes et al, 2015; Shen et al, 2009; Virtanen et al, 2012; Zhao et al, 2016) is discussed in Methods and Appendix Table S3 .
MOFA is implemented as well-documented open-source software that facilitates a range of important downstream analyses, including visualization and automatic characterization of the inferred factors (Methods). Taken together, these functionalities provide a powerful and versatile tool for disentangling sources of variation in multi-omic studies.
Model validation and comparison on simulated data
First, to validate MOFA, we simulated data from its generative model, varying the number and the likelihood model of different views, the number of latent factors and other parameters (Methods, Appendix Table S1). We found that MOFA was able to accurately reconstruct the latent dimension, except in settings with large numbers of factors or proportions of missing values (Appendix Figure S1 ). We also found that models with non-Gaussian likelihood models improved the fit when simulating binary or count data (Appendix Figure S2 and S3) .
We also compared MOFA to two previously reported latent variable models for multi-omics integration: GFA (Leppäaho & Kaski, 2017) and iCluster (Mo et al, 2013) . Over a range of simulations, we observed that GFA and iCluster tended to infer redundant factors (Appendix Figure S4 ) and were less accurate in recovering patterns of factor activity across views (Appendix Figure S5 ). MOFA is also computationally more efficient than GFA and iCluster ( Figure EV1) . For example, the training on the CLL data, which we consider next, required 45 minutes with MOFA vs. 34 hours with GFA and 5-6 days with iCluster.
Application to Chronic Lymphocytic Leukaemia
We applied MOFA to a study of chronic lymphocytic leukaemia (CLL), which combined ex-vivo drug response measurements with somatic mutation status, transcriptome profiling and DNA methylation assays (Dietrich et al, 2018) (Fig. 2a) . Notably, nearly 40% of the 200 samples were profiled with some but not all 'omics types; such a missing value scenario is not uncommon in large cohort studies, and MOFA is designed to cope with it (Methods; Appendix Figure S1 ). MOFA was also configured to combine different likelihood models in order to accommodate the combination of continuous and discrete data types in this study.
MOFA identified 10 factors (minimum explained variance 2% in at least one assay; Methods).
These were robust to algorithm initialisation as well as subsampling of the data ( Appendix Figure   S6 ,7). The factors were largely orthogonal, capturing independent sources of variation ( Appendix Figure S6 ). Among these, Factors 1 and 2 were active in most assays, indicating broad roles in multiple molecular layers (Fig. 2b) . In contrast, other factors such as Factor 3 or Factor 5 were specific to two data modalities, and Factor 4 was active in a single data modality only.
Cumulatively, the 10 factors explained 41% of variation in the drug response data, 38% in the mRNA data, 24% in the DNA methylation data and 24% in the mutation data ( Fig. 2c) .
We also trained MOFA when excluding individual views to probe their redundancy, finding that factors that were active in multiple assays could still be recovered, while the identification of others was dependent on a specific data type (Appendix Figure S8) . In comparison to GFA (Leppäaho & Kaski, 2017) and iCluster (Mo et al, 2013) , MOFA was more consistent in identifying factors across random restarts and their cross-assay activity (Appendix Figure S9 ).
MOFA identifies important clinical markers in CLL and reveals an underappreciated axis of variation attributed to oxidative stress.
As part of the downstream pipeline, MOFA provides different strategies to use the loadings of the features on each factor to identify their etiology (Fig. 1) . For example, based on the top weights in the mutation data, Factor 1 was aligned with the somatic mutation status of the immunoglobulin heavy-chain variable region gene (IGHV), while Factor 2 aligned with trisomy of chromosome 12 ( Fig. 2d,e ). Thus, MOFA correctly identified two major axes of molecular disease heterogeneity and aligned them with two of the most important clinical markers in CLL (Fabbri & Dalla-Favera, 2016; Zenz et al, 2010) (Fig. 2d,e ).
IGHV status, the marker corresponding to Factor 1, is a surrogate of the differentiation state of the tumor's cell of origin and the level of activation of the B-cell receptor. While in clinical practice this axis of variation is generally considered binary (Fabbri & Dalla-Favera, 2016) , our results indicate a more complex substructure ( Fig. 3a, Appendix Figure S10 ). At the current resolution, this factor was consistent with three subgroup models such as proposed by (Oakes et al, 2016; Queiros et al, 2015 ) (Appendix Figure S11) , although there is suggestive evidence for an underlying continuum.
MOFA connected this factor to multiple molecular layers (Appendix Figure S12, S13), including changes in the expression of genes previously linked to IGHV status (Maloum et al, 2009; Morabito 6 et al, 2015; Plesingerova et al, 2017; Trojani et al, 2012; Vasconcelos et al, 2005) (Fig. 3b,c) and with drugs that target kinases in or downstream of the B-cell receptor (Fig. 3d,e ).
Despite their clinical importance, the IGHV and the trisomy 12 factors accounted for less than 20% of the variance explained by MOFA, suggesting the existence of other sources of heterogeneity.
One example is Factor 5, which was active in the mRNA and drug response data. Analysis of the weights in the mRNA revealed that this factor tagged a set of genes enriched for oxidative stress and senescence pathways ( Fig. 2f, Figure EV2a) , with the top weights corresponding to heat shock proteins (HSPs) (Figure EV2b,c) , genes that are essential for protein folding and are upregulated upon stress conditions (Åkerfelt et al, 2010; Srivastava, 2002) . Although genes in HSP pathways are upregulated in some cancers and have known roles in tumour cell survival (Trachootham et al, 2009 ), thus far this gene family has received little attention in the context of CLL. Consistent with this annotation based on the mRNA data, we observed that the drugs with the strongest weights on Factor 5 were associated with response to oxidative stress, such as target reactive oxygen species (ROS), DNA damage response and apoptosis (Figure EV2d,e ).
Factor 4 captured 9% of variation in the mRNA data, and gene set enrichment analysis on the mRNA loadings suggested etiologies related to immune response pathways and T-cell receptor signalling ( Fig. 2f) , likely due to differences in cell type composition between samples: While the samples are comprised mainly of B-cells, Factor 4 revealed a possible contamination with other cell types such as T-cells and monocytes (Appendix Figure S14 ). Factor 3 explained 11% of variation in the drug response data capturing differences in the samples' general level of drug sensitivity (Geeleher et al, 2016 ) (Appendix Figure S15 ).
MOFA identifies outlier samples and accurately imputes missing values
Next, we explored the relationship between inferred factors and clinical annotations, which can be missing, mis-annotated or inaccurate, since they are frequently based on single markers or imperfect surrogates (Westra et al, 2011) . Since IGHV status is the major biomarker impacting on clinical care, we assessed the consistency between the inferred continuous Factor 1 and this binary marker. For 176 out of 200 patients, the MOFA factor was in agreement with the clinical IGHV status, and MOFA further allowed for classifying 12 patients that lacked clinically measured IGHV status (Figure EV3a,b) . Interestingly, MOFA assigned 12 patients to a different group than suggested by their clinical IGHV label. Upon inspection of the underlying molecular data, nine of these cases showed intermediate molecular signatures, suggesting that they are borderline cases that are not well captured by the binary classification; the remaining three cases were clearly discordant (Figure EV3c,d) . Additional independent drug response assays as well as whole exome sequencing data confirmed that these cases are outliers within their IGHV group (Fig. 
EV3e,f).
As incomplete data is a common problem in studies that combine multiple high-throughput assays, we assessed the ability of MOFA to fill in missing values within assays as well as when entire data modalities are missing for some of the samples. For both imputation tasks, MOFA yielded more accurate predictions than other established imputation strategies, including imputation by featurewise mean, SoftImpute (Mazumder et al, 2010 ) and a k-nearest neighbour method (Troyanskaya et al, 2001) (Figure EV4, Appendix Figure S16 ), and MOFA was more robust than GFA, especially in the case of missing assays (Appendix Figure S17 ).
Latent factors inferred by MOFA are predictive of clinical outcomes
Finally, we explored the utility of the latent factors inferred by MOFA as predictors in models of clinical outcomes. Three of the 10 factors identified by MOFA were significantly associated with time to next treatment (Cox regression, Methods, FDR<1%, Fig. 4a,b) : the cell of origin related Factor 1, and two Factors, 7 and 8, associated with chemo-immunotherapy treatment prior to sample collection. In particular, Factor 7 captures del17p and TP53 mutations as well as differences in methylation patterns of oncogenes (Fluhr et al, 2016; Garg et al, 2014 ) (Appendix Figure S18 ), while Factor 8 is associated with WNT signalling (Appendix Figure S19 ).
We also assessed the prediction performance when combining the 10 MOFA factors in a multivariate Cox regression model. Notably, this model yielded higher prediction accuracy than models using factors derived from conventional PCA ( Fig. 4c) , individual molecular features (Appendix Figure S20 ) or MOFA factors derived from only a subset of the available data modalities (Appendix Figure S8b ,d) (assessed using cross-validation, Methods). Notably, the predictive value of MOFA factors was similar to clinical covariates (such as Lymphocyte doubling time) that are used to guide treatment decisions (Appendix Figure S21 ).
MOFA reveals coordinated changes in single cells between the transcriptome and the epigenome along a differentiation trajectory
As multi-omic approaches are also beginning to emerge in single cell biology (Angermueller et al, 2016; Clark et al, 2018; Colomé-Tatché & Theis, 2018; Guo et al, 2017; Macaulay et al, 2015) , we investigated the potential of MOFA to disentangle the heterogeneity observed in such studies. We applied MOFA to a data set of 87 mouse embryonic stem cells (mESCs), comprising of 16 cells cultured in '2i' media, which induces a naive pluripotency state, and 71 serum-grown cells, which commits cells to a primed pluripotency state poised for cellular differentiation (Angermueller et al, 2016) . All cells were profiled using single-cell methylation and transcriptome sequencing, which provides parallel information of these two molecular layers (Fig. 5a ). We applied MOFA to disentangle the observed heterogeneity in the transcriptome and the CpG methylation at three different genomic contexts: promoters, CpG islands and enhancers.
MOFA identified 3 factors driving cell-cell heterogeneity (minimum explained variance of 2%,
Methods):
While Factor 1 is shared across all data modalities (7% variance explained in the RNA data and between 53% and 72% in the methylation data sets), Factors 2 and 3 are active primarily in the RNA data (Fig. 5b,c) . Gene loadings revealed that Factor 1 captured the cell's transition from naive to primed pluripotent states, pinpointing markers for naive pluripotency such as Rex1/Zpf42, Tbx3, Fbxo15 and Essrb (Mohammed et al, 2017) ( Fig. 5d and Figure EV5a ). MOFA connected these transcriptomic changes to coordinated changes of the genome-wide DNA methylation rate across all genomic contexts ( Figure EV5b ) as previously described both in vitro (Angermueller et al, 2016) and in vivo (Auclair et al, 2014) . Factor 2 captured a second axis of differentiation from the primed pluripotency state to a differentiated state with highest RNA loadings for known differentiation markers such as keratins and annexins (Fuchs, 1988) (Fig. 5d and Figure EV5c ). Finally, Factor 3 captured the cellular detection rate, a known technical covariate associated with cell quality (Finak et al, 2015 ) (Appendix Figure S22 ).
Jointly, Factors 1 and 2 captured the entire differentiation trajectory from naive pluripotent cells via primed pluripotent cells to differentiated cells, (Fig. 5e ), illustrating the importance of learning continuous latent factors rather than discrete sample assignments. Multi-omics clustering algorithms such as SNF or iCluster (Mo et al, 2013; Shen et al, 2009 ) were only capable of distinguishing cellular subpopulations, but not of recovering continuous processes such as cell differentiation (Appendix Figure S23 ).
Discussion
Multi-Omics Factor Analysis (MOFA) is an unsupervised method for decomposing the sources of heterogeneity in multi-omics data sets. We applied MOFA to high-dimensional and incomplete multi-omics profiles collected from patient-derived tumour samples and to a multi-omics single-cell study of mESCs.
First, in the CLL study, we demonstrated that our method is able to identify major drivers of variation in a clinically and biologically heterogeneous disease. Most notably, our model identified previously known clinical markers as well as novel putative molecular drivers of heterogeneity, some of which were predictive of clinical outcome. Additionally, since MOFA factors capture variations of multiple features and data modalities, inferred factors can help to mitigate assay noise, thereby increasing the sensitivity for identifying molecular signatures compared to using individual features or assays. Our results also demonstrate that MOFA can leverage information from multiple omics layers to accurately impute missing values from sparse profiling datasets and guide the detection of outliers, e.g. due to mislabelled samples or sample swaps.
In a second application, we used MOFA for the analysis of single-cell multi-omics data. This use case illustrates the advantage of learning continuous factors, rather than discrete groups, enabling MOFA to recover a differentiation trajectory by combining information from two sparsely profiled molecular layers.
While applications of factor models for integrating different data types were reported previously (Akavia et al, 2010; Lanckriet et al, 2004; Mo et al, 2013; Shen et al, 2009 ), MOFA provides unique features (Methods, Appendix Table S3 ) that enable the interpretable reconstruction of the underlying factors and accommodating different data types as well as different patterns of missing data. MOFA is available as open source software and includes semi-automated analysis pipelines allowing for in-depth characterisations of inferred factors. Taken together, this will foster the accessibility of interpretable factor models for a wide range of multi-omics studies.
Although we have addressed important challenges for multi-omics applications, MOFA is not free of limitations. The model is linear, which means that it can miss strongly non-linear relationships between features within and across assays (Buettner & Theis, 2012) . Non-linear extensions of MOFA may address this, although as with any models in high-dimensional spaces, there will be trade-offs between model complexity, computational efficiency and interpretability (Damianou et al, 2016) . A related area of work is to incorporate prior information on the relationships between individual features. For example, future extensions could make use of pathway databases within each omic type (Buettner et al, 2017) or priors that reflect relationships given by the 'dogma of molecular biology'. In addition, new likelihoods and noise models could expand the value of MOFA in data sets with specific statistical properties that hamper the application of traditional statistical methods, including zero-inflated data (i.e. scRNA-seq (Pierson & Yau, 2015) ) or binomial distributed data (i.e. splicing events (Huang & Sanguinetti, 2017) ). Finally, while here we use approximate Bayesian inference and focus attention on the resulting point estimates of inferred factors, future extensions could attempt a more comprehensive Bayesian treatment that propagates evidence strength and estimation uncertainties to diagnostics and downstream analyses.
Methods

Code availability
An open source implementation of MOFA is available from https://github.com/bioFAM/MOFA.
Code to reproduce all the analyses presented is available at https://github.com/PMBio/MOFA_CLL.
Data availability
The CLL data were obtained from (Dietrich et al, 2018) and are available at the European Genome-phenome Archive under accession EGAS00001001746 and data tables as R objects can be downloaded from http://pace.embl.de/. The single-cell data were obtained from (Angermueller et al, 2016) and are available in the Gene Expression Omnibus under accession GSE74535. All data used are contained within the MOFA vignettes and can be downloaded as from https://github.com/bioFAM/MOFA.
Multi-Omic Factor Analysis Model
Starting from M data matrices Y 1 ,..,Y M of dimensions N × Dm, where N is the number of samples and Dm the number of features in data matrix m, MOFA decomposes these matrices as
Here, Z denotes the factor matrix (common for all data matrices) and W m denote the weight matrices for each data matrix m (also referred to as view m in the following). m denotes the viewspecific residual noise term, with its form depending on the specifics of the data-type (see section
Noise model).
The model is formulated in a probabilistic Bayesian framework, where we place prior distributions on all unobserved variables of the model (see plate diagram in Appendix Figure S24) , i.e. the factors Z, the weight matrices W m and the parameters of the residual noise term. In particular, we use a standard normal prior for the factors Z and employ sparsity priors for the weight matrices (see next section).
Model regularization
An appropriate regularization of the weight matrices is essential for the model's ability to disentangle variation across data sets and yield interpretable factors. MOFA uses a two-level regularization: The first level encourages view-and factor-wise sparsity, thereby allowing to directly identify which factor is active in which view. The second level encourages feature-wise sparsity, thereby typically resulting in a small number of features with active weights. To encode these sparsity levels we combine an Automatic Relevance Determination prior for the first type of the sparsity with a spike-and-slab prior for the second. For amenable inference we model the spikeand-slab prior by parameterizing the weights as a product of a Bernoulli distributed random variable and a normally distributed random variable: =̂, where ∼ Ber( ) and ̂ ∼ (0,1/ ). To automatically learn the appropriate level of regularization for each factor and view, we use uninformative conjugate prior on , which controls the strength of factor k in view m, and on , which determines the feature-wise sparsity level of factor k in view m (see Appendix Supplementary Methods, section 2 for details).
Noise model
MOFA supports the combination of different noise models to integrate diverse data types, including continuous, binary and count data. A standard noise model for continuous data is the Gaussian noise model assuming iid heteroscedastic residuals m , i.e. ∼ (0,1/ ) , with Gamma prior on the precision parameters . MOFA further supports noise models for binary and count data that are not appropriately modelled using a Gaussian likelihood. In the current version, MOFA models count data using a Poisson model and binary data by using a Bernoulli model. Here, the model likelihood is given by ∼ ( ( : : )) and ∼ Ber( ( : : )), respectively, where ( ) = log(1 + ) and denotes the logistic function ( ) = (1 + − ) −1 .
Parameter inference
For scalability, we make use of a variational framework with a mean-field approximation (Blei et al, 2017 
Model training and selection
An important part of the training is the determination of the number of factors. While the inferred factors are robust under different initializations (e.g. Appendix Figure S6c,d) the optimization landscape is non-convex and the algorithm is not guaranteed to identify a global optimum. Results presented here are based on 10-25 random restarts, selecting the model with the highest ELBO (e.g. Appendix Figure S6b ).
Downstream analysis for factor interpretation and annotation
As part of MOFA we provide the R package MOFAtools, containing a semi-automated pipeline for the characterisation and interpretation of the latent factors. In all downstream analyses we use the expectations of the model components under the posterior distributions inferred by the variational framework.
The first step, after a model has been trained, is to disentangle the variation explained by each factor in each view. To this end, we compute the fraction of total variance explained (R 2 ) by factor k in view m as
as well as the fraction of variance explained per view taking into account all factors
Here, denotes the feature-wise mean. Subsequently, each factor is characterised by three complementary analyses:
1. Ordination of the samples in factor space: Visualise a low-dimensional representation of the main drivers of sample heterogeneity.
Inspection of top features with largest weight:
The loadings can give insights into the biological process underlying the heterogeneity captured by a latent factor. Due to scale differences between assays, the weights of different views are not directly comparable. For simplicity, we scale each weight vector by its absolute value.
Feature set enrichment analysis:
We combine the signal from functionally related sets of features (e.g., gene sets) to derive a feature-set based annotation. By default, we use a parametric t-test comparing the means of the foreground set (the weights of features that belong to a set G) and the background set (the weights of features that do not belong to the set G), similar to (Frost et al, 2015) .
Relationship to existing methods
MOFA builds upon the statistical framework of group factor analysis (Bunte et al, 2016; Khan et al, 2014; Klami et al, 2015; Leppäaho & Kaski, 2017; Virtanen et al, 2012; Zhao et al, 2016) and
shares components of the iCluster methods (Mo et al, 2013; Shen et al, 2009 ) as shown in Appendix Table S3 . Here we describe the connections in more detail:
iCluster: In contrast to MOFA, iCluster uses in a each view the same extent of regularization for all factors, which may be sufficient for the purpose of clustering (the primary application of iCluster), however it results in a reduced ability for distinguishing factors that drive variation in distinct subsets of views (Appendix Figure S5) . Additionally, unlike MOFA and GFA, iCluster does not handle missing values and is computationally demanding (Figure EV1) , as it requires re-fitting the model for a large range of different penalty parameters and choices of the model dimension.
Group factor analysis: While the underlying model of MOFA is closely connect to the most recent GFA implementation (Leppäaho & Kaski, 2017) , GFA is restricted to Gaussian observation noise.
In terms of implementation, MOFA adds a burn-in period during training without sparsity constraints to avoid early splitting of factors and actively drops factors below the variance threshold as described in Model training and selection. In contrast, GFA directly uses sparsity constraints from the beginning and maintains all factors that have non-zero weights. In terms of inference, MOFA is implemented using a variational approach while GFA uses a Gibbs sampling scheme. In terms of scalability (Figure EV1) , both methods are linear in the model's parameters. The higher intercept and slope for GFA is mainly driven by the presence of missing values in the data. This, together with the inability to drop factors (Appendix Figure S4 ) renders GFA considerably slower in applications to real data.
Details on the simulation studies
Model validation
To validate MOFA we simulated data from the generative model for a varying number of views (M=1,3,...,21), features (D=100,500,…,10000), factors (K=5,10,...,60), missing values (from 0% to 90%) as well as for non-Gaussian likelihoods (Poisson, Bernoulli) (see Appendix Table S1 for simulation parameters). We assessed the ability of MOFA to recover the true number of factors in the different settings across 10 realizations for every configuration. All trials were started with a high number of factors (K=100), and inactive factors were pruned as described in the Model training and selection section.
Model comparison
To compare MOFA with other approaches we simulated data from the generative model with Table S1 shows in more detail the simulation parameters used in each setting.
Details on the CLL analysis
Data processing
The data was obtained from (Dietrich et al, 2018) where details on the data generation and processing can be found. Briefly, the data consist of somatic mutations (combination of targeted and whole exome sequencing), RNA expression (RNA-Seq), DNA methylation (Illumina arrays) and ex-vivo drug response screens (ATP-based CellTiter Glo assay 
Model training and selection
We trained MOFA on the data for 25 random initializations with a variance threshold of 2% and selected a model for downstream analysis as described in Model training and selection.
Gene set enrichment analysis
Gene set enrichment analysis was performed on the Reactome gene sets (Fabregat et al, 2015) as described above. Resulting p-values are adjusted for multiple testing on each factor using Benjamini-Hochberg (Benjamini & Hochberg, 1995) procedure to control the false discovery rate at 1%.
Imputation
To compare imputation performance, we trained MOFA on the subset of samples with all measurements (N=121) and masked at random either single values or all measurements for given samples in the drug response. After model training the masked values were imputed directly from the model equation (1) and the accuracy was assessed in terms of mean squared error on the true (masked) values. For both settings we fixed the number of factors in MOFA to K=10. To investigate the dependence on K for imputation and compare to GFA we re-ran the same masking experiments varying K=1,...,20.
Survival Analysis
Associations of the inferred factors to clinical outcome were assessed using patients' time to next treatment as response variable in a Cox model on all samples having this information, i.e. N=174
of which 96 are uncensored cases. For univariate associations (as shown in Figure 4a , Appendix Figure S21 ) we scaled all predictors to ensure comparability of the hazard ratios and we rotated factors, which are rotational invariant, such that their Hazard ratio is greater or equal to 1. To investigate the predictive power of different datasets, we used a multivariate Cox model and compared Harrell's C-index of predictions in a stratified 5-fold cross-validation scheme. As predictors we included the top 10 principal components on the data of each single view, a concatenated data set ('all') as well as the ten MOFA factors. Missing values in a view were imputed by the feature-wise mean. In a second set of models we used the complete set of all features in a view with a ridge penalty in the Cox model as implemented in the R package glmnet.
For the Kaplan-Meier plots an optimal cut-point on each factor was determined to define the two groups using the maximally selected rank statistics as implemented in the R package survminer with p-values based on a Log-Rank test between the resulting groups.
Details on the scMT analysis
The data were obtained from (Angermueller et al, 2016) , where details on the data generation and pre-processing can be found. Briefly for each CpG site we calculated a binary methylation rate from the ratio of methylated read counts to total read counts. RNA expression data were normalised using (Lun et al, 2016) . To fit MOFA, we considered the top 5000 most variable genes with a maximum dropout of 90%, and the top 5000 most variable CpG sites with a minimum coverage of 10% across cells. Model selection was performed as described for the CLL data and factors were inactivated below a minimum explained variance of 2%. For the clustering analysis using SNF and iCluster, the optimal number of clusters was selected using BIC criterion. Genes highlighted in orange were previously described as prognostic markers in CLL and associated with IGHV status (Maloum et al, 2009; Morabito et al, 2015; Plesingerova et al, 2017; Trojani et al, 2012; Vasconcelos et al, 2005) . points on each factor were chosen using maximally selected rank statistics (Hothorn & Lausen, 2003) , and p-values were calculated using a Log-rank test on the resulting groups. in the mRNA data. Labeled genes in Factor 1 are known markers of pluripotency (Mohammed et al, 2017) and genes labeled in Factor 2 are known differentiation markers (Fuchs, 1988) .(e) Scatterplot of Factors 1 and 2. Colors denote culture conditions. The grey arrow illustrates the differentiation trajectory from naive pluripotent cells via primed pluripotent cells to differentiated cells. 
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